Treatment of hepatocellular carcinoma: a systematic review.
TLDR
Stage-based approach to therapy not only provides acceptable outcomes but also improves the quality of life of HCC patients, whichusses the current standards and trends in the treatment of H CC.Abstract:
Hepatocellular carcinoma (HCC) is one of the most common malignancies, with an increasing incidence. With advances in surgical techniques and instrumentation and the development of molecular-target drugs, a number of potentially curative treatments have become available. Management of HCC patients depends on the stage of their tumor. Liver resection remains the first choice for very early-stage HCC, but it is being challenged by local ablative therapy. For early-stage HCC that meet the Milan criteria, liver transplantation still offers a better outcome; however, local ablative therapy can be a substitute when transplantation is not feasible. Local ablation is also used as a bridging therapy toward liver transplantation. HCC recurrence is the main obstacle to successful treatment, and there is currently no effective means of preventing or treating HCC recurrence. Transarterial therapy is considered suitable for intermediate-stage HCC, while sorafenib is recommended for advanced-stage HCC. This stage-based approach to therapy not only provides acceptable outcomes but also improves the quality of life of HCC patients. Because of the complexity of HCC, therapeutic approaches must be adapted according to the characteristics of each individual patient. This review discusses the current standards and trends in the treatment of HCC.read more
Citations
More filters
Journal ArticleDOI
Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models
Zhen Lu,Bingfeng Zuo,Renwei Jing,Xianjun Gao,Quan Rao,Zhili Liu,Han Qi,Hongxing Guo,HaiFang Yin +8 more
TL;DR: Evidence is provided that AFP-enriched DEXs can trigger potent antigen-specific antitumor immune responses and reshape the tumor microenvironment in HCC mice and thus provide a cell-free vaccine option for HCC immunotherapy.
Journal ArticleDOI
Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro.
TL;DR: It is demonstrated that tumor cell–derived exosomes (TEXs), displaying an array of HCC antigens, can elicit a stronger immune response than cell lysates in vitro and in vivo, and can improve the HCC tumor microenvironment.
Journal ArticleDOI
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
Tadaaki Arizumi,Kazuomi Ueshima,Tomohiro Minami,Masashi Kono,Hirokazu Chishina,Masahiro Takita,Satoshi Kitai,Tatsuo Inoue,Norihisa Yada,Satoru Hagiwara,Yasunori Minami,Toshiharu Sakurai,Naoshi Nishida,Masatoshi Kudo +13 more
TL;DR: Conclusions: Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC, and administration of sorAFenib is therefore recommended in such circumstances of TACE treatment failure.
Journal ArticleDOI
Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.
Isabella Lurje,Zoltan Czigany,Jan Bednarsch,Christoph Roderburg,Peter Isfort,Ulf P. Neumann,Ulf P. Neumann,Georg Lurje +7 more
TL;DR: The topic of multimodal treatment strategies in HCC is addressed, highlighting a multidisciplinary treatment approach to further improve outcome in patients with underlying chronic liver disease.
Journal ArticleDOI
The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma
TL;DR: The mechanism by which Hif-1 is regulated and how HIF-1 mediates the biological effects of hypoxia in tissues are described, which could shed light on new therapeutic approaches for the treatment of HCC.
References
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Management of hepatocellular carcinoma: An update
Jordi Bruix,Morris Sherman +1 more
TL;DR: The American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) were updated in 2010 as discussed by the authors.
AASLD PRACTICE GUIDELINE Management of Hepatocellular Carcinoma: An Update
Jordi Bruix,Morris Sherman +1 more
TL;DR: Since the publication of the American Association for the Study of Liver Diseases (AASLD) practice guidelines on the management of hepatocellular carcinoma (HCC) in 2005, new information has emerged that requires that the guidelines be updated.
Journal ArticleDOI
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
Vincenzo Mazzaferro,Enrico Regalia,Roberto Doci,Salvatore Andreola,A. Pulvirenti,Federico Bozzetti,F. Montalto,Mario Ammatuna,Alberto Morabito,Leandro Gennari +9 more
TL;DR: Liver transplantation is an effective treatment for small, unresectable hepatocellular carcinomas in patients with cirrhosis and after four years, the actuarial survival rate was 75 percent and the rate of recurrence-free survival was 83 percent.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more